Form 4: Alto Neuroscience Reprices COO's Stock Options to $2.35 Amidst Share Price Decline

Alto Neuroscience, Inc. has repriced 321,000 employee stock options for its Chief Operating Officer, Michael Conick Hanley Jr., to an exercise price of $2.35 per share, effective July 3, 2025, aligning with the closing stock price on that date.

Summary

• Chief Operating Officer Michael Conick Hanley Jr. had a total of 321,000 employee stock options repriced.
• The repricing was effective on July 3, 2025, and applied to options with original exercise prices greater than $2.35 per share.
• The new exercise price for all repriced options is $2.35 per share, which was the closing price of Alto Neuroscience's common stock on the repricing date.
• The repriced options include 8,000 shares originally priced at $14.88, 188,000 shares originally priced at $12.40, and 125,000 shares originally priced at $4.20.
• Vesting schedules, expiration dates, and the total number of shares underlying the repriced options remain unchanged.
• A condition stipulates that if an employee exercises a repriced option before the end of a one-year retention period, they will be required to pay the original, higher exercise price per share.

Sentiment

Score: 3

Explanation: While the repricing benefits the executive by making options in-the-money, the underlying reason for the repricing (a significant drop in stock price) is a negative indicator for the company's performance and investor sentiment. The one-year retention clause also adds a slight constraint.

Positives

• The exercise price of 321,000 employee stock options for the Chief Operating Officer has been significantly reduced to $2.35 per share, making them more 'in-the-money' and potentially more valuable to the holder.
• The repricing aligns the option exercise price with the current market value, potentially re-incentivizing the executive and restoring the motivational aspect of their equity compensation.

Negatives

• The necessity of repricing stock options from significantly higher prices ($14.88, $12.40, $4.20) down to $2.35 implies a substantial decline in the company's stock value since the original grant dates.
• A condition requires the employee to pay the original, higher exercise price if options are exercised within a one-year retention period, which limits the immediate benefit and liquidity for the executive.

Risks

• The repricing of stock options, particularly to a significantly lower exercise price, often indicates a substantial decline in the company's stock value, which could reflect underlying business challenges or negative market sentiment.
• The one-year retention period, during which the original exercise price must be paid if options are exercised, could disincentivize immediate exercise and potentially impact executive liquidity or retention if the stock price does not recover.

Future Outlook

The vesting schedules for the repriced options remain unchanged, with 25% of 188,000 shares having vested on May 20, 2025, and the remainder vesting monthly thereafter. For 125,000 shares, 25% are set to vest on February 5, 2026, with monthly installments thereafter, all subject to the Reporting Person's continuous service.

Industry Context

NA

Stakeholder Impact

• Shareholders: The repricing of executive stock options to a significantly lower price may signal a substantial decline in the company's stock value, potentially eroding shareholder confidence and value.
• Employees: The repricing of options for the COO, if extended to other employees, could improve morale and retention by restoring the incentive value of their equity compensation, but it also highlights past stock underperformance.

Next Steps

• Continued monthly vesting of 1/48th of the shares underlying the 188,000 and 125,000 options, subject to continuous service.
• Exercise of repriced options by the Chief Operating Officer, subject to the one-year retention period condition.

Key Dates

Recommendation

Keywords

Alto Neuroscience, ANRO, Stock Option Repricing, Form 4, Executive Compensation, Employee Stock Option, Insider Transaction, Chief Operating Officer, Equity Compensation